{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:26:26Z","timestamp":1791901586282,"version":"4.3.4"},"reference-count":83,"publisher":"Cold Spring Harbor Laboratory","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cold Spring Harb Perspect Biol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1101\/cshperspect.a028456","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T20:50:22Z","timestamp":1501879822000},"page":"a028456","source":"Crossref","is-referenced-by-count":342,"title":["Interleukin (IL-6) Immunotherapy"],"prefix":"10.1101","volume":"10","author":[{"given":"Toshio","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Narazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadamitsu","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"246","published-online":{"date-parts":[[2017,8,4]]},"reference":[{"key":"2018101515250673000_10.8.a028456.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1992.tb01407.x"},{"key":"2018101515250673000_10.8.a028456.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60532-5"},{"key":"2018101515250673000_10.8.a028456.3","doi-asserted-by":"publisher","DOI":"10.1038\/ni1584"},{"key":"2018101515250673000_10.8.a028456.4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000317"},{"key":"2018101515250673000_10.8.a028456.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.2843985"},{"key":"2018101515250673000_10.8.a028456.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.1083901"},{"key":"2018101515250673000_10.8.a028456.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(00)89102-1"},{"key":"2018101515250673000_10.8.a028456.8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1017385108"},{"key":"2018101515250673000_10.8.a028456.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.10623"},{"key":"2018101515250673000_10.8.a028456.10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.2.736"},{"key":"2018101515250673000_10.8.a028456.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112802"},{"key":"2018101515250673000_10.8.a028456.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1678"},{"key":"2018101515250673000_10.8.a028456.13","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.2002.6415"},{"key":"2018101515250673000_10.8.a028456.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208742"},{"key":"2018101515250673000_10.8.a028456.15","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1242\/jcs.111.13.1853","article-title":"Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells","volume":"111","year":"1998","journal-title":"J Cell Sci"},{"key":"2018101515250673000_10.8.a028456.16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1631560"},{"key":"2018101515250673000_10.8.a028456.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60250-0"},{"key":"2018101515250673000_10.8.a028456.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05252-1"},{"key":"2018101515250673000_10.8.a028456.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"2018101515250673000_10.8.a028456.20","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1073\/pnas.1424774112","article-title":"Interleukin-6\/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension","volume":"112","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"2018101515250673000_10.8.a028456.21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken363"},{"key":"2018101515250673000_10.8.a028456.22","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2009.45"},{"key":"2018101515250673000_10.8.a028456.23","doi-asserted-by":"publisher","DOI":"10.1042\/bj2650621"},{"key":"2018101515250673000_10.8.a028456.24","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90411-7"},{"key":"2018101515250673000_10.8.a028456.25","doi-asserted-by":"publisher","DOI":"10.1038\/324073a0"},{"key":"2018101515250673000_10.8.a028456.26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.1.228"},{"key":"2018101515250673000_10.8.a028456.27","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830181122"},{"key":"2018101515250673000_10.8.a028456.28","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1691"},{"key":"2018101515250673000_10.8.a028456.29","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/blood.V74.4.1241.1241","article-title":"Interleukin-6 is a potent thrombopoietic factor in vivo in mice","volume":"74","year":"1989","journal-title":"Blood"},{"key":"2018101515250673000_10.8.a028456.30","doi-asserted-by":"publisher","DOI":"10.1038\/332083a0"},{"key":"2018101515250673000_10.8.a028456.31","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): A phase 2, randomised controlled trial","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"2018101515250673000_10.8.a028456.32","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040391"},{"key":"2018101515250673000_10.8.a028456.33","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.03.040185.001025"},{"key":"2018101515250673000_10.8.a028456.34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V74.1.1.1","article-title":"The biology of interleukin-6","volume":"74","year":"1989","journal-title":"Blood"},{"key":"2018101515250673000_10.8.a028456.35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115806"},{"key":"2018101515250673000_10.8.a028456.36","doi-asserted-by":"publisher","DOI":"10.1126\/science.1411569"},{"key":"2018101515250673000_10.8.a028456.37","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90333-6"},{"key":"2018101515250673000_10.8.a028456.38","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw171"},{"key":"2018101515250673000_10.8.a028456.39","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650110113"},{"key":"2018101515250673000_10.8.a028456.40","first-page":"60","article-title":"Interleukin-6 in sepsis and capillary leakage syndrome","volume":"32","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"2018101515250673000_10.8.a028456.41","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.39740","article-title":"A prospective open label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica","volume":"68","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2018101515250673000_10.8.a028456.42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.10.5962"},{"key":"2018101515250673000_10.8.a028456.43","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.10.5.2327"},{"key":"2018101515250673000_10.8.a028456.44","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20120994"},{"key":"2018101515250673000_10.8.a028456.45","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.immuni.2016.03.011","article-title":"CD5: A new partner for IL-6","volume":"44","year":"2016","journal-title":"Immunity"},{"key":"2018101515250673000_10.8.a028456.46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1307419110"},{"key":"2018101515250673000_10.8.a028456.47","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151289"},{"key":"2018101515250673000_10.8.a028456.48","doi-asserted-by":"publisher","DOI":"10.1038\/nature07924"},{"key":"2018101515250673000_10.8.a028456.49","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035"},{"key":"2018101515250673000_10.8.a028456.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"2018101515250673000_10.8.a028456.51","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2865"},{"key":"2018101515250673000_10.8.a028456.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.04.029"},{"key":"2018101515250673000_10.8.a028456.53","doi-asserted-by":"publisher","DOI":"10.1126\/science.8511589"},{"key":"2018101515250673000_10.8.a028456.54","doi-asserted-by":"publisher","DOI":"10.1038\/43219"},{"key":"2018101515250673000_10.8.a028456.55","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.V82.4.1120.1120","article-title":"Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130","volume":"82","year":"1993","journal-title":"Blood"},{"key":"2018101515250673000_10.8.a028456.56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200420945"},{"key":"2018101515250673000_10.8.a028456.57","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.17.12.3399"},{"key":"2018101515250673000_10.8.a028456.58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1182\/blood.V95.1.56","article-title":"Improvement in Castleman\u2019s disease by humanized anti-interleukin-6 receptor antibody therapy","volume":"95","year":"2000","journal-title":"Blood"},{"key":"2018101515250673000_10.8.a028456.59","doi-asserted-by":"publisher","DOI":"10.1002\/art.20303"},{"key":"2018101515250673000_10.8.a028456.60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4602"},{"key":"2018101515250673000_10.8.a028456.61","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15326-3"},{"key":"2018101515250673000_10.8.a028456.62","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.1.503"},{"key":"2018101515250673000_10.8.a028456.63","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80334-9"},{"key":"2018101515250673000_10.8.a028456.64","first-page":"851","article-title":"Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth","volume":"53","year":"1993","journal-title":"Cancer Res"},{"key":"2018101515250673000_10.8.a028456.65","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.3.961"},{"key":"2018101515250673000_10.8.a028456.66","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.17.12848"},{"key":"2018101515250673000_10.8.a028456.67","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq275"},{"key":"2018101515250673000_10.8.a028456.68","first-page":"1","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2018101515250673000_10.8.a028456.69","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204573"},{"key":"2018101515250673000_10.8.a028456.70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063842"},{"key":"2018101515250673000_10.8.a028456.71","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.797"},{"key":"2018101515250673000_10.8.a028456.72","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0022"},{"key":"2018101515250673000_10.8.a028456.73","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010611-134715"},{"key":"2018101515250673000_10.8.a028456.74","first-page":"33","article-title":"Tocilizumab: An updated review of its use in the treatment of rheumatoid arthritis and its application for other immune-mediated diseases","volume":"5","year":"2013","journal-title":"Clin Med Insights Ther"},{"key":"2018101515250673000_10.8.a028456.75","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295"},{"key":"2018101515250673000_10.8.a028456.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.01.009"},{"key":"2018101515250673000_10.8.a028456.77","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0020"},{"key":"2018101515250673000_10.8.a028456.78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623"},{"key":"2018101515250673000_10.8.a028456.79","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"2018101515250673000_10.8.a028456.80","doi-asserted-by":"publisher","DOI":"10.1126\/science.3136546"},{"key":"2018101515250673000_10.8.a028456.81","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60454-7"},{"key":"2018101515250673000_10.8.a028456.82","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","article-title":"Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman\u2019s disease","volume":"74","year":"1989","journal-title":"Blood"},{"key":"2018101515250673000_10.8.a028456.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.003"}],"container-title":["Cold Spring Harbor Perspectives in Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/cshperspect.a028456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T16:34:38Z","timestamp":1659285278000},"score":1,"resource":{"primary":{"URL":"http:\/\/cshperspectives.cshlp.org\/lookup\/doi\/10.1101\/cshperspect.a028456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,4]]},"references-count":83,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,1]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1101\/cshperspect.a028456"],"URL":"https:\/\/doi.org\/10.1101\/cshperspect.a028456","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727877439.793572024","asserted-by":"object"}]},"ISSN":["1943-0264"],"issn-type":[{"value":"1943-0264","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,4]]}}}